Tucanat 150 mg

Tucanat 150 mg is a prescription medicine containing Tucatinib 150 mg, shown as a Natco product. It is an oral targeted anticancer medicine mainly used in selected HER2-positive cancer cases, depending on diagnosis, previous treatment history, test reports, and the oncologist’s treatment plan. Tiny bottle, huge oncology paperwork, because apparently cells needed a plot twist.

Tucatinib is used in combination therapy for adults with advanced unresectable or metastatic HER2-positive breast cancer, including cases with brain metastases, after prior anti-HER2 treatment. It is also used with trastuzumab for selected RAS wild-type, HER2-positive unresectable or metastatic colorectal cancer after prior chemotherapy, according to official prescribing information.

Composition:

Tucatinib – 150 mg

Key Information:

Brand Name: Tucanat
Strength: 150 mg
Active Ingredient: Tucatinib
Dosage Form: Tablets
Medicine Type: Anticancer medicine / Targeted therapy / HER2 tyrosine kinase inhibitor
Manufacturer/Brand Shown: Natco
Common Use: Treatment of selected HER2-positive cancers
Other Prescribed Uses: HER2-positive metastatic breast cancer and RAS wild-type HER2-positive metastatic colorectal cancer, as advised by an oncologist
Administration: Oral use
Category: Prescription medicine
Pack Size: 60 tablets, as visible on the pack

How It Works:

Tucanat 150 mg works by blocking HER2 tyrosine kinase activity, which may help slow the growth and spread of cancer cells that depend on HER2 signaling. Official information lists tucatinib tablets in 50 mg and 150 mg strengths, and the recommended adult dose for approved combination regimens is generally 300 mg orally twice daily, but the final dose must be decided by the treating oncologist.

Potential Indications:

• HER2-positive metastatic breast cancer
• HER2-positive advanced unresectable breast cancer
• Breast cancer with brain metastases in selected cases
• RAS wild-type HER2-positive metastatic colorectal cancer
• Other oncologist-directed use based on diagnosis and test reports

Dosage & Storage:

Take only as directed by a qualified healthcare professional.
Follow the dosage instructions printed on the label or prescribed by the doctor.
Swallow the tablet whole; do not crush, chew, or split unless specifically advised.
Tucatinib may be taken with or without food as directed in official labeling.
Store in a cool, dry place away from direct sunlight and moisture.
Keep out of reach of children.

Important Safety Information:

Tucatinib should be used carefully under medical supervision, especially in patients with liver problems, diarrhea, dehydration risk, pregnancy risk, or those taking other cancer medicines.

Possible side effects may include:

• Diarrhea
• Nausea
• Vomiting
• Mouth sores
• Loss of appetite
• Fatigue
• Skin rash
• Hand-foot skin reaction
• Abdominal pain
• Fever
• Anemia
• Increased liver function test values

Serious risks include severe diarrhea and liver problems, so symptoms such as severe loose motions, dehydration, yellowing of skin or eyes, dark urine, unusual tiredness, or right-side abdominal pain should be reported to a doctor immediately.

Label Verification:

Please double-check the physical product label before listing or use, including the product name, strength, active ingredient, manufacturer details, batch number, expiry date, storage instructions, dosage directions, route of administration, and packaging information.

General Information Disclaimer:

The information provided here is for general educational and product-identification purposes only. It should not be considered medical advice, diagnosis, or treatment. Always consult a qualified healthcare professional before starting, stopping, or changing any medication regimen.